Innovating Vaccines

ImmBio is developing next-generation vaccines against serious infectious disease targets, utilising its proprietary technology platforms to directly induce immunity via dendritic cells.

Find out more
About us

About us

ImmBio has an experienced team of scientists and executives based in state of the art facilities at the Babraham Research Campus, Cambridge UK. ImmBio develops innovative vaccines that induce broad immunity against pathogens.

Find out more
Technology

Technology

Our vaccines protect by targeting antigens directly to dendritic cells, using two proprietary complimentary technology platforms. Our lead platform, ImmBioVax™ is designed against bacterial vaccine targets.

Find out more
Pipeline

Pipeline

Our ImmBioVax™ pipeline includes vaccines against pneumococcal disease, meningitis and tuberculosis. ImmBio technology platforms can be directed against new vaccine targets where strain variation or resistance is a problem.

Find out more
Partner

Partner

ImmBio's strategy is to develop innovative vaccines in partnership with leading centres of expertise and to out-license late-stage development for subsequent commercialisation. Contact ImmBio for corporate opportunities. details.

Find out more